William F Garner

Address:

685 Abbay Way, Sparks, NV 89431

VIN:

5TFBV54157X031904

Make:

TOYOTA

Model:

TUNDRA

Year:

2007

US Patent:

20210251944, Aug 19, 2021

Filed:

Feb 17, 2021

Appl. No.:

17/177665

Inventors:

- Vancouver, CA
Jeffrey A. Bacha - Vancouver, CA
William J. Garner - San Francisco CA, US

Assignee:

Del Mar Pharmaceuticals (BC) Ltd. - Vancouver

International Classification:

A61K 31/336
A61K 45/06
A61K 31/047
C12Q 1/6886

Abstract:

Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI-1 gene are disclosed. These methods employ an alkylating hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative or analog of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative or analog of dibromodulcitol. The compositions can include such alkylating hexitol derivatives. The methods can further include administration of a BH3 mimetic, and the compositions can further include a BH3 mimetic. In subjects having a dysregulation of the AHI-1 gene, the methods can further include the administration of an agent modulating the expression or activity of the AHI-1 gene or AHI-1 protein, and the compositions can further include such an agent.

US Patent:

20160220537, Aug 4, 2016

Filed:

Jul 25, 2014

Appl. No.:

14/907728

Inventors:

William J. GARNER - San Francisco CA, US
Amie FRANKLIN - Mountain View CA, US
John ROTHMAN - Lebanon NJ, US
- Lebanon NJ, US

International Classification:

A61K 31/4178
A61K 47/48

Abstract:

The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

US Patent:

20150182490, Jul 2, 2015

Filed:

Jun 24, 2013

Appl. No.:

14/409909

Inventors:

- Vancouver, CA
Jeffrey A. Bacha - Vancouver, CA
William J. Garner - San Francisco CA, US

International Classification:

A61K 31/336
C12Q 1/68
A61K 45/06

Abstract:

Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI1 gene are disclosed. These methods employ an alkylating hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative or analog of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative or analog of dibromodulcitol. The compositions can include such alkylating hexitol derivatives. The methods can further include administration of a BH3 mimetic, and the compositions can further include a BH3 mimetic. In subjects having a dysregulation of the AHI1 gene, the methods can further include the administration of an agent modulating the expression or activity of the AHI1 gene or AHI1 protein, and the compositions can further include such an agent.